FISH: NSCLC (NON-SMALL CELL LUNG CANCER) ALK1 & ROS1

A PHP Error was encountered

Severity: 8192

Message: json_decode(): Passing null to parameter #1 ($json) of type string is deprecated

Filename: models/Product_model.php

Line Number: 247

Backtrace:

File: /home/lilj9s9ph51h/public_html/truemedix/models/Product_model.php
Line: 247
Function: json_decode

File: /home/lilj9s9ph51h/public_html/truemedix/controllers/Pages.php
Line: 138
Function: get_related

File: /home/lilj9s9ph51h/public_html/index.php
Line: 316
Function: require_once

FISH: NSCLC (NON-SMALL CELL LUNG CANCER) ALK1 & ROS1

248 Ratings

Rs 16,200 Rs 12,000

26 % OFF

ANAPLASTIC LYMPHOMA KINASE (ALK) AND C-ROS1 ONCOGENE (ROS1) REARRANGEMENTS REPRESENT THE TWO MOST FREQUENT FUSION TARGETS IN LUNG ADENOCARCINOMA. ALK GENE HAS MORE THAN 20 KNOWN REARRANGEMENT PARTNER GENES, WITH 15 VARIANTS OF THE MOST COMMON EML4-ALK FUSION. ROS1 HAS 7 PARTNERS DESCRIBED SO FAR IN NSCLC. THE FREQUENCY OF ALK REARRANGEMENT IS 3-7% & ROS1 REARRANGEMENT IS 1-2% IN NSCLC. IT IS WELL KNOWN THAT PATIENTS WITH ALK/ROS1 REARRANGEMENT BENEFIT FROM CRIZOTINIB THERAPY.

Get a Free Call

To Know about Services Detail or any Enquiry.

A PHP Error was encountered